New York, June 4, 2026, 05:07 (ET)
Psyence Biomedical Ltd. shares traded at $3.95 in early premarket action, up 2.5 cents from the last close. A U.S. Schedule 13D showed Psyence Labs Ltd. holding 1,146,159 shares, or 30.05%, with full voting and disposal power. According to the filing, Psyence Labs could add to its stake, sell down, or hedge based on market or company moves.
Nasdaq’s main session wasn’t open yet. The exchange lists premarket hours from 4:00 a.m. to 9:30 a.m. Eastern, then regular trading from 9:30 a.m. to 4:00 p.m. June 4 isn’t on Nasdaq’s 2026 U.S. stock-market holiday list.
Psyence’s latest filing puts focus back on a key shareholder, a supply chain partner, and an old non-cash share swap just as investors are set to get a normal-session price. In February, Psyence said PsyLabs issued 2,900 ordinary shares worth $5 million for 1,146,159 Psyence common shares. No cash moved in the deal.
For a small psychedelic-drug developer, this isn’t just about the cap table. It ties straight to supply. Psyence is selling PsyLabs’ Good Manufacturing Practice, or GMP, credentials as a key offering for making regulated ibogaine and psilocybin. CEO Jody Aufrichtig said last month that “global interest in ibogaine research continues to accelerate” and said Psyence wanted to show the “highly specialized process” needed for compliant ibogaine. GlobeNewswire
Psyence is still early in its clinical work. The company said in April it started dosing the first patient in its Phase IIb trial, looking at NPX-5, a 25 mg nature-derived psilocybin, for adjustment disorder in cancer patients under palliative care. The mid-stage study is set up to check for safety and potential effectiveness. Dr. Neil Maresky, global head of clinical development, called for “disciplined execution” and “high-quality data.” Psyence Biomedical
Investors aren’t just waiting on trial news. The group of psychedelic drug developers like Compass Pathways and AtaiBeckley jumped in April. That move came after a U.S. order to speed up the FDA’s review of psychedelic treatments. Jefferies analyst Andrew Tsai called the move an “official stamp of validation” for the sector. RBC’s Brian Abrahams said it’s a “substantial step towards diminishing regulatory risk.” Reuters
Psyence isn’t moving on the same catalyst as Compass or AtaiBeckley. Compass is mostly known for its late-stage psilocybin trials in depression that hasn’t responded to other treatments. AtaiBeckley has picked up attention for its psychedelic mental-health work. But Psyence is focused on a tighter pitch. Its angle is control over its own supply chain—ownership and manufacturing—and the question is whether that’s a story investors want to pay up for.
But the risks are plain. Investors may worry about dilution and governance issues over strategic fit, and there’s still basic biotech risk in the drug pipeline. Psyence is warning that clinical trials cost a lot, take time and might not work out. It also said regulators might not accept clinical data from other countries, and that holdups in trial enrollment, manufacturing, supply or regulatory sign-off could stall its plans.
Psyence heads into Thursday’s open with one big question: does having a 30% holder in its supply chain count as real backing, or just fuel worries about control and dilution? The first trades of the session should make things clearer.
